Abivax (ABVX) Change in Account Payables (2024 - 2026)
Abivax (ABVX) posted quarterly Change in Account Payables of -$9.4 million for Q1 2026, down 170.23% year-over-year from $13.4 million in Q1 2025, and down 200.55% quarter-over-quarter from $9.4 million in Q4 2025.
Abivax (ABVX) Change in Account Payables (2024 - 2026) Analysis & Trends
Abivax's Change in Account Payables history runs 3 years deep, the most recent figure standing at -$9.4 million for Q1 2026.
- In Q1 2026, Change in Account Payables fell 170.23% year-over-year to -$9.4 million; the TTM figure through Mar 2026 stood at -$31.7 million (down 820.02% YoY), while the FY2025 annual figure was -$7.2 million, down 96.42% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$9.4 million, down from $9.4 million in the prior quarter.
- The five-year high for Change in Account Payables was $15.0 million in Q3 2024, with the low at -$32.7 million in Q3 2025.
- The 3-year median for Change in Account Payables is $1.1 million (2025), against an average of -$2.4 million.
- Peak annual rise in Change in Account Payables reached 5088.78% in 2025, while the deepest fall reached 318.09% in 2025.
- Abivax's Change in Account Payables stood at $180592.6 in 2024, then jumped by 5088.78% to $9.4 million in 2025, then sank by 200.55% to -$9.4 million in 2026.
- Business Quant data shows ABVX's Change in Account Payables at -$9.4 million in Q1 2026, $9.4 million in Q4 2025, and -$32.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.03 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 37.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 520,137.79 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Abivax | 9.39 Bn | 9.39 Bn | - | -9.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.42 Mn |
| Mar 31, 2026 | -9.42 Mn |
| Dec 31, 2025 | 9.37 Mn |
| Dec 31, 2025 | 9.37 Mn |
| Sep 30, 2025 | -32.73 Mn |
| Sep 30, 2025 | -32.73 Mn |
| Jun 30, 2025 | 1.11 Mn |
| Jun 30, 2025 | 1.11 Mn |
| Mar 31, 2025 | 13.42 Mn |
| Mar 31, 2025 | 13.42 Mn |
| Dec 31, 2024 | 180,592.62 |
| Dec 31, 2024 | 180,592.62 |
| Sep 30, 2024 | 15.01 Mn |
| Sep 30, 2024 | 15.01 Mn |
| Jun 30, 2024 | -24.21 Mn |
| Jun 30, 2024 | -24.21 Mn |
| Mar 31, 2024 | 5.65 Mn |
| Mar 31, 2024 | 5.65 Mn |